These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 16389899

  • 1. Weight gain and insulin treatment.
    Larger E.
    Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S51-4S56. PubMed ID: 16389899
    [Abstract] [Full Text] [Related]

  • 2. At last, a weight neutral insulin?
    Fritsche A, Häring H.
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S41-6. PubMed ID: 15306837
    [Abstract] [Full Text] [Related]

  • 3. Does insulin detemir have a role in reducing risk of insulin-associated weight gain?
    Hermansen K, Davies M.
    Diabetes Obes Metab; 2007 May; 9(3):209-17. PubMed ID: 17391147
    [Abstract] [Full Text] [Related]

  • 4. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 5. The role of insulin detemir in overweight type 2 diabetes management.
    Demssie YN, Younis N, Soran H.
    Vasc Health Risk Manag; 2009 Jul; 5(3):553-60. PubMed ID: 19590589
    [Abstract] [Full Text] [Related]

  • 6. Analysis of glycaemic control and weight change in patients initiated with human or analog insulin in an US ambulatory care setting.
    McAdam-Marx C, Bouchard J, Aagren M, Nelson R, Brixner D.
    Diabetes Obes Metab; 2010 Jan; 12(1):54-64. PubMed ID: 19758356
    [Abstract] [Full Text] [Related]

  • 7. Insulin therapy and type 2 diabetes: management of weight gain.
    McFarlane SI.
    J Clin Hypertens (Greenwich); 2009 Oct; 11(10):601-7. PubMed ID: 19817944
    [Abstract] [Full Text] [Related]

  • 8. Insulin detemir in the treatment of type 1 and type 2 diabetes.
    Philips JC, Scheen A.
    Vasc Health Risk Manag; 2006 Oct; 2(3):277-83. PubMed ID: 17326333
    [Abstract] [Full Text] [Related]

  • 9. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ.
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [Abstract] [Full Text] [Related]

  • 10. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W, Lockhart I, Kotchie RW, Aagren M, LeReun C.
    Pharmacology; 2008 May; 82(2):156-63. PubMed ID: 18679040
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of the weight-increasing effects of biphasic analog and regular NPH insulin mixtures in patients with Type 2 diabetes mellitus.
    Temizel M, Mert M, Bozbey C, Arman Y, Cevizci E, Altintaş N, Cetin Ölek A.
    J Diabetes; 2010 Dec; 2(4):250-5. PubMed ID: 20923498
    [Abstract] [Full Text] [Related]

  • 12. Insulin-associated weight gain in diabetes--causes, effects and coping strategies.
    Russell-Jones D, Khan R.
    Diabetes Obes Metab; 2007 Nov; 9(6):799-812. PubMed ID: 17924864
    [Abstract] [Full Text] [Related]

  • 13. Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.
    Schwartz SS, Jellinger PS, Herman ME.
    Postgrad Med; 2016 Aug; 128(6):609-19. PubMed ID: 27210018
    [Abstract] [Full Text] [Related]

  • 14. [Type 2 diabetes: hypoglycemia risk, weight gain... Will there soon be a new alternative to insulin?].
    MMW Fortschr Med; 2006 Sep 14; 148(37):54. PubMed ID: 17036907
    [No Abstract] [Full Text] [Related]

  • 15. Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile.
    Jansen HJ, Vervoort G, van der Graaf M, Tack CJ.
    Neth J Med; 2010 Nov 14; 68(11):359-66. PubMed ID: 21116029
    [Abstract] [Full Text] [Related]

  • 16. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May 14; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 17. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
    Davies MJ, Derezinski T, Pedersen CB, Clauson P.
    Diabetes Technol Ther; 2008 Aug 14; 10(4):273-7. PubMed ID: 18715200
    [Abstract] [Full Text] [Related]

  • 18. An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog.
    Raslova K.
    Vasc Health Risk Manag; 2010 Jun 01; 6():399-410. PubMed ID: 20539842
    [Abstract] [Full Text] [Related]

  • 19. Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
    Brown A, Guess N, Dornhorst A, Taheri S, Frost G.
    Diabetes Obes Metab; 2017 Dec 01; 19(12):1655-1668. PubMed ID: 28509408
    [Abstract] [Full Text] [Related]

  • 20. Insulin detemir: a new basal insulin analogue.
    Soran H, Younis N.
    Diabetes Obes Metab; 2006 Jan 01; 8(1):26-30. PubMed ID: 16367879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.